Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data

The Lancet Neurology

Volumn 12, Issue 7, 2013, Pages 637-649

  Tabrizi, Sarah J ^a   Scahill, Rachael I ^a   Owen, Gail ^a   Durr, Alexandra ^b   Leavitt, Blair R ^c   Roos, Raymund A ^d   Borowsky, Beth ^e   Landwehrmeyer, Bernhard ^f   Frost, Chris ^g   Johnson, Hans ^h   Craufurd, David ^i,j   Reilmann, Ralf ^k   Stout, Julie C ^l   Langbehn, Douglas R ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^f UNIVERSITY OF ULM   (Germany)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h Department of Psychiatry ^*  (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY OF MÜNSTER   (Germany)

^l MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN;

ADULT; APATHY; ARTICLE; BRAIN SIZE; CAG REPEAT; CANADA; CLINICAL ASSESSMENT; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FEMALE; FRANCE; FUNCTIONAL STATUS; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR ACTIVITY; NETHERLANDS; NEUROIMAGING; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; ONSET AGE; PHENOTYPIC VARIATION; PINCH STRENGTH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PUTAMEN; SURVIVAL; TASK PERFORMANCE; UNITED KINGDOM; WHITE MATTER; AGE DISTRIBUTION; BEHAVIOR; BRAIN ATROPHY; FOLLOW UP; HETEROZYGOTE; PHENOTYPE; RISK FACTOR;

AFFECT; AGED; BRAIN; COGNITION; DISEASE PROGRESSION; FEMALE; HAND STRENGTH; HUMANS; HUNTINGTON DISEASE; LEAST-SQUARES ANALYSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOSTRIATUM; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PSYCHOMOTOR PERFORMANCE; REPETITIVE SEQUENCES, NUCLEIC ACID; SURVIVAL ANALYSIS;

EID: 84879032355     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70088-7     Document Type: Article

References (33)

1. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009, 8:791-801.
2. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011, 10:31-42.
3. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012, 11:42-53.
4. Ross CA, Tabrizi SJ Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011, 10:83-98.
5. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011, 82:405-410.
6. Unified Huntington's Disease Rating Scale: reliability and consistenty. Mov Disord 1996, 11:136-142. Huntington Study Group.
7. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004, 65:267-277.
8. Shoulson I, Fahn S Huntington disease: clinical care and evaluation. Neurology 1979, 29:1-3.
9. Benjamini Y, Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995, 57:289-300.
10. Benjamini Y, Yekateuli D The control of the false discovery rate in multiple testing under dependency. Ann Statist 2001, 29:1165-1188.
11. Hobbs NZ, Henley SM, Ridgway G, et al. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 2010, 81:756-763.
12. Hobbs NZ, Barnes J, Frost C, et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010, 31:1036-1041.
13. Majid DS, Aron AR, Thompson W, et al. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. Mov Disord 2011, 26:2544-2551.
14. Majid DS, Stoffers D, Sheldon S, et al. Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year. Mov Disord 2011, 26:1481-1488.
15. Stout JC, Jones R, Labuschagne I, et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 2012, 83:687-694.
16. Witjes-Ane MN, Mertens B, van Vugt JPP, Bachoud-Levi AC, van Ommen GJ, Roos RAC Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease. J Neuropsychiatry Clin Neurosci 2007, 19:310-317.
17. Rowe KC, Paulsen JS, Langbehn DR, et al. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 2010, 24:435-442.
18. Aylward EH, Liu D, Nopoulos PC, et al. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 2012, 71:822-828.
19. Paulsen JS, Nopoulos PC, Aylward E, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010, 82:201-207.
20. Squitieri F, Cannella M, Simonelli M, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther 2009, 15:1-11.
21. Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012, 83:612-619. Group tP-HIotHS.
22. Sritharan A, Egan GF, Johnston L, et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry 2010, 81:257-262.
23. Michell AW, Goodman AO, Silva AH, Lazic SE, Morton AJ, Barker RA Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. J Neurol 2008, 255:1145-1152.
24. Lefaucheur JP, Menard-Lefaucheur I, Maison P, et al. Electrophysiological deterioration over time in patients with Huntington's disease. Mov Disord 2006, 21:1350-1354.
25. Rosenblatt A, Kumar BV, Mo A, Welsh CS, Margolis RL, Ross CA Age, CAG repeat length, and clinical progression in Huntington's disease. Mov Disord 2012, 27:272-276.
26. Thompson JC, Harris J, Sollom AC, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J Neuropsychiatry Clin Neurosci 2012, 24:53-60.
27. Rosenblatt A Neuropsychiatry of Huntington's disease. Dialogues Clin Neurosci 2007, 9:191-197.
28. Rosas HD, Reuter M, Doros G, et al. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Mov Disord 2011, 26:1691-1697.
29. Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. Neuropsychology 2012, 26:664-669.
30. Wexler NS Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004, 101:3498-3503.
31. Spires TL, Grote HE, Garry S, et al. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur J Neurosci 2004, 19:2799-2807.
32. Bouchard J, Truong J, Bouchard K, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci 2012, 32:18259-18268.
33. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group 1. Neurology 2000, 54:452-458.